RNV.AU Renerve Ltd
- Market cap
- AUD 15.6M
- P/E
- -
- P/B
- 4.92x
- ROE
- -175.4%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is RNV.AU undervalued?
Graham numberThe Graham number of Renerve Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Renerve Ltd fundamental analysis
3 of 21 checks passedROE 0/2
Low return on equity (-175.4%), below 10%.
ROA 0/1
Return on assets (-122.9%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-23.4%) is below the industry median (-5.3%).
Revenue Growth 2/2
Revenue grew 58.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.3 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (4.9x) is above the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Renerve Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Renerve Ltd
ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers Empliq Dermal, an acellular dermal matrix (ADM) sour…
Full company profileRenerve Ltd financial statements
Renerve Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 578K | 128K | 177K | 272K | 510K |
| Gross Profit | 578K | 128K | 177K | 245K | 271K |
| Operating Income | -1.76M | -2.20M | -3.12M | -4.45M | -6.52M |
| EBITDA | - | -1.65M | -2.54M | -3.44M | -5.45M |
| Net Income | -1.76M | -1.80M | -2.98M | -3.73M | -5.57M |
| EPS | -0.01 | -0.01 | -0.02 | -0.03 | -0.03 |
| Balance Sheet | |||||
| Total Assets | 0.00 | 0.00 | 7.92M | 6.19M | 4.53M |
| Total Liabilities | 0.00 | 0.00 | 503K | 999K | 1.36M |
| Shareholders' Equity | 0.00 | 0.00 | 7.42M | 5.20M | 3.18M |
| Cash & Short-term Investments | - | - | 7.49M | 4.75M | 1.49M |
| Cash Flow | |||||
| Capital Expenditure | 116K | 45.8K | 4.98K | 65.3K | 147K |
| Free Cash Flow | -1.98M | -1.52M | -2.30M | -3.05M | -5.95M |
| Ratios | |||||
| ROE | - | - | -40.2% | -71.9% | -175.4% |
| ROA | - | - | -37.7% | -60.3% | -122.9% |
| Net Profit Margin | -304.0% | -1,403.4% | -1,682.9% | -1,374.2% | -1,091.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Renerve Ltd dividends
Renerve Ltd has not paid dividends in the last 5 fiscal years.
Who owns Renerve Ltd
- Insiders 67.45%
- Institutions 1.29%
- Public & others 31.26%
- Shares outstanding 174M
- Free float 92.8M
Renerve Ltd company profile
- Company name
- Renerve Ltd
- Ticker
- RNV.AU
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 157 Heidelberg Road, Northcote, VIC, Australia, 3070
- Phone
- 61 3 9482 3940
- Website
- renerve.com.au
About Renerve Ltd
ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers Empliq Dermal, an acellular dermal matrix (ADM) sourced from donated human skin and designed to replace lost or damaged dermal tissue; bionic nerve, a novel combination polymer technology; and Nerve Guide Matrix for treating more severe nerve injuries but eliminating the need for patients to undergo additional sural nerve harvesting under the NervAlign brand. The company was incorporated in 2016 and is headquartered in Northcote, Australia.
Renerve Ltd management
3- Dr. Julian John Chick BSc (Hons)CEO & Executive Director · born 1969
- Mr. David Lilja CTA, M.B.A.CFO & Company Secretary
- Dr. Alex Adamides FRACS, M.D.Chief Medical Officer & Member of Scientific Advisory Board